The Atriva Approach
ATRIVA is changing the philosophy and strategy of antiviral drug development. Instead of targeting the virus directly, the ATRIVA compounds are directed against a cellular factor of the host cell. In order to ensure efficient replication, the virus needs to activate this factor. ATRIVA’s lead compound ATR-002 prevents the virus-induced activation of the cellular factor and consequently viral replication.
Various viruses need to activate this cellular factor for replication, including viruses responsible for respiratory tract infections. Thus, ATR-002 might not only be effective against influenza virus but also against others viruses that cause influenza like illness (ILI). Consequently, ATR-002 will be developed as the first-in-class compound against influenza- and other respiratory viruses.
ATRIVA aims to develop antiviral therapies against severe respiratory viral infections.
Great potential against influenza virus and potentially corona viruses due to antiviral and immunomodulating activity of ATRIVA’s lead product ATR-002. Phase I clinical trial successfully completed, Phase II under preparation.
For detail and further readings:
PHaasbach et al 2017; The MEK-inhibitor CI-1040 displays a broad anti-influenza virus activity in vitro and provides a prolonged treatment window compared to standard of care in vivo. Antiviral Research 142:178-184.